Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Despite Recent Setbacks At Pfizer, R&D Chief Is Optimistic About R&D Innovation

This article was originally published in The Pink Sheet Daily

Executive Summary

Mikael Dolsten cites Pfizer's latest efforts to be more efficient, improve R&D productivity, and implement precision medicine as key to its rebound.

You may also be interested in...



Ziarco Picks Up Pfizer Assets, Series A Round

A former Pfizer VP used four of the pharma’s programs to secure private financing from an unlikely investor and got the pharma to buy into the new start-up. Now, he hopes to develop next generation treatments for inflammatory and allergic diseases.

R&D Restructurings Aim To Placate Investors While Pharma Waits For Results

In response to poor R&D productivity and declining revenue as drug patents expire, Big Pharma companies have shrunk drastically to keep shareholders happy while they try to retool moribund R&D strategies.

R&D Restructurings Aim To Placate Investors While Pharma Waits For Results

In response to poor R&D productivity and declining revenue as drug patents expire, Big Pharma companies have shrunk drastically to keep shareholders happy while they try to retool moribund R&D strategies.

Related Content

Topics

UsernamePublicRestriction

Register

PS072182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel